Abstract
Dementia, which can be induced by diverse factors, is a clinical syndrome characterized by the decline of cognitive function. Behavioral and psychological symptoms of dementia (BPSD) include depression, agitation, and aggression. Dementia causes a heavy burden on patients and their caregivers. Patients with BPSD should be assessed comprehensively by practitioners and offered appropriate non-pharmacologic and pharmacologic therapy. Nonpharmacologic therapy has been recommended as the basal treatment for BPSD; however, pharmacologic therapy is required under many situations. Medications, including antipsychotic agents, antidepressants, sedative and hypnotic agents, mood stabilizers, cholinesterase inhibitors, and amantadine, are extensively used in clinical practice. We have reviewed the progression of pharmacologic therapy for BPSD.
Keywords: Alzheimer’s disease, antipsychotic, behavioral and psychological symptoms of dementia, dementia, drug, psychiatric symptoms.
Graphical Abstract
Current Neuropharmacology
Title:Drug Therapy for Behavioral and Psychological Symptoms of Dementia
Volume: 14 Issue: 4
Author(s): Feng Wang, Ting-Yi Feng, Shilin Yang, Maurice Preter, Jiang-Ning Zhou and Xiao-Ping Wang
Affiliation:
Keywords: Alzheimer’s disease, antipsychotic, behavioral and psychological symptoms of dementia, dementia, drug, psychiatric symptoms.
Abstract: Dementia, which can be induced by diverse factors, is a clinical syndrome characterized by the decline of cognitive function. Behavioral and psychological symptoms of dementia (BPSD) include depression, agitation, and aggression. Dementia causes a heavy burden on patients and their caregivers. Patients with BPSD should be assessed comprehensively by practitioners and offered appropriate non-pharmacologic and pharmacologic therapy. Nonpharmacologic therapy has been recommended as the basal treatment for BPSD; however, pharmacologic therapy is required under many situations. Medications, including antipsychotic agents, antidepressants, sedative and hypnotic agents, mood stabilizers, cholinesterase inhibitors, and amantadine, are extensively used in clinical practice. We have reviewed the progression of pharmacologic therapy for BPSD.
Export Options
About this article
Cite this article as:
Wang Feng, Feng Ting-Yi, Yang Shilin, Preter Maurice, Zhou Jiang-Ning and Wang Xiao-Ping, Drug Therapy for Behavioral and Psychological Symptoms of Dementia, Current Neuropharmacology 2016; 14 (4) . https://dx.doi.org/10.2174/1570159X14666151208114232
DOI https://dx.doi.org/10.2174/1570159X14666151208114232 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Markers of Atherosclerotic Disease: What do they Mean? Current Opinion and Future Trends
Current Pharmaceutical Design Reduction of Aβ Levels in the Sprague Dawley Rat After Oral Administration of the Functional g-Secretase Inhibitor, DAPT: A Novel Non- Transgenic Model for Aβ Production Inhibitors
Current Pharmaceutical Design New Developments of Clinical Trial in Immunotherapy for Alzheimer's Disease
Current Pharmaceutical Biotechnology Topical Discoveries on Multi-Target Approach to Manage Alzheimer’s Disease
Current Drug Metabolism Bioinformatic Analysis of HIV-1 Entry and Pathogenesis
Current HIV Research New Pharmacologic Approaches to Prevent Thromboembolism in Patients with Atrial Fibrillation
Current Vascular Pharmacology AD Vaccines: Conclusions and Future Directions
CNS & Neurological Disorders - Drug Targets Pleiotropic Effects of Drugs Inhibiting the Renin-Angiotensin-Aldosterone System
Current Pharmaceutical Design The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
Current Medicinal Chemistry Serotonin Receptor Binding Characteristics of Geissoschizine Methyl Ether, an Indole Alkaloid in Uncaria Hook
Current Medicinal Chemistry Substrates and Inhibitors of Human Multidrug Resistance Associated Proteins and the Implications in Drug Development
Current Medicinal Chemistry An Observational Study of the Needs and Quality of Life Amongst Patients in the Treatment of Alzheimers Dementia with Cholinesterase Inhibitors
Current Aging Science Risk Reduction and Prevention of Alzheimer's Disease: Biological Mechanisms of Diet
Current Alzheimer Research Emerging Evidence for the Role of Neurotransmitters in the Modulation of T Cell Responses to Cognate Ligands
Central Nervous System Agents in Medicinal Chemistry Hsp20 Protects Neuroblastoma Cells from Ischemia/Reperfusion Injury by Inhibition of Apoptosis via a Mechanism that Involves the Mitochondrial Pathways
Current Neurovascular Research Diagnoses of Pathological States Based on Acetylcholinesterase and Butyrylcholinesterase
Current Medicinal Chemistry Pharmacological Countermeasures for the Acute Radiation Syndrome
Current Molecular Pharmacology Roles and Therapeutic Potential of Metallothioneins in Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Anderson-Fabry Disease in Children
Current Pharmaceutical Design PET Molecular Imaging of Hypoxia in Ischemic Stroke: An Update
Current Vascular Pharmacology